Utilized for schizophrenia and bipolar depression to manage psychiatric symptoms and support mood balance.
Mechanism of Action
Lurasidone antagonizes dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors. It also acts as a partial agonist at serotonin 5-HT1A receptors, providing antipsychotic effects with improved cognitive and depressive profiles.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
18 hours (half-life)
Contraindications
Concurrent use of potent CYP3A4 inhibitors, Hypersensitivity to lurasidone
Information related to Latuda is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
